An observational study in Liver Diseases, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by University of Chicago · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Liver Diseases with a site in United States — 46 open to participants now, 60 under way, 5 of them phase 3. Liver Diseases · United States.
Among the 369 studies in Liver Diseases with a site in United States, this one is the 18th largest by planned enrollment of the 90 observational ones that give a count, is one of 25 that started in 2022, is one of 91 observational ones, reaches primary completion later than 9 of the 58 other live ones, and was the 295th registered.
825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.
Browse Liver Diseases studies →46 of the 369 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States
Ages 18–80
West Virginia University · Sites in United States
Ages 18+
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 6–17
Incyte Corporation · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 72 · Phase 2 75 · Phase 3 30 · Phase 4 21
First in 1988; this study’s year is marked. 25 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 200 across 262 observational studies indexed under Liver Diseases.
Median enrollment 48 across the 270 interventional studies, 153 across the 90 observational. Of the 276 that completed or were terminated, 115 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 369 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 4 studies filed under Liver Diseases — fewer than ten, so there is no comparison to draw.
22 of the studies in Liver Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04612764Baylor College of MedicineLiver Disease in Urea Cycle Disorders | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT05953337ABK BiomedicalRadioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | 2027-02 |
| NCT05264051University of ChicagoMAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease | 2027-03-01 |
| NCT07746999Corey DeStefanoNorth Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health | 2027-03-15 |
Add all 22 to your calendar (.ics) → With an account.
Among the 369 studies in Liver Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam.
Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated.
Pts. hospitalized with acute hepatic decompensation Pts. with hepatobiliary neoplasia Pts. undergoing TIPS placement Pts. with chroinic liver disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Waitlist Mortality
Death prior to liver transplant or delisting from enrollment in the study
Time frame: Measured up to 10 years out from enrollment
Started Apr 2022 (actual). Primary completion is estimated for Mar 2027, 58 months after the start.
Of 103 non-industry observational studies under Liver Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 124. This study's planned 58 months is above that.
Counting every sponsor, half of 117 studies reached it within 47 months; a quarter within 22 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.